CD Skripsi

Efek Inhibitor Proteasom Terhadap Kadar Il-6 Serum Pada Tikus Model Aterosklerosis

---

to play an important role in the process of initiation, progression and
complications of atherosclerosis, although there is still controversy. On the other
hand, IL-6, a multifunctional cytokine, is an independent risk factor for
atherosclerosis. Proteasome inhibitors can suppress the release of proinflammatory
cytokines such as IL-6 and induce apoptosis of activated immune
cells. The purpose of this study was to analyze the effect of proteasome inhibitor
on IL-6 serum levels in atherosclerosis rats. This experimental study used 18 male
Wistar strain rats (Rattus novergicus) aged 10 weeks which were divided into
control group (I), atherosclerosis group (II), and atherosclerosis with bortezomib
treatment (III). Atherosclerosis induction was carried out by providing
atherogenic feed with a composition of 2% cholesterol, 0.2% cholic acid, 5% goat
fat and 100% standard diet and induced with vitamin D3 (700,000 IU/kg). Lowdose
bortezomib (50 g/kgBW) was given in two doses, on the 1st and 3rd day
intraperitoneally. Serum IL-6 levels were measured using the ELISA technique.
The results of this study showed that the highest levels of IL-6 were group II
(atherosclerosis) 46.78±9.55 ng/ml and the lowest group III
(atherosclerosis+bortezomib) 30.81±5.84 ng/ml. There was a decrease of IL-6
levels in the atherosclerosis+bortezomib group although it was not statistically
significant.
Keywords: atherosclerosis, IL-6 serum, proteasome, bortezomib

---

التوفّر

معلومات بالتفصيل

عنوان السلسلة

-

رقم الطلب

08 01.121 (0067)

ناشر

Pekanbaru : Universitas Riau – Kedokteran – Pendidikan Dokter., 2021

التوريق

xii, 37 hlm.: ill.: 29 cm

اللغة

Indonesia

ردمك/ردمد

-

تَصْنِيفٌ

08 01.121 (0067)

نوع المحتويات

-

نوع الوسائط

-

نوع الناقل

-

الإصدارة

-

موضوع

PENDIDIKAN DOKTER

تفاصيل محددة

-

بيان المسؤولية

ELFITRA

نسخ أخرى/مرتبطة

ملف مرفق

التعليقات

---

You must be logged in to post a comment